Memantine Augmentation in Obsessive-Compulsive Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder

NCT00956085

Obsessive-Compulsive Disorder

COMPLETED PHASE2

Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder

NCT00674219

Obsessive-Compulsive Disorder Generalized Anxiety Disorder

COMPLETED PHASE3

Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder

NCT00869505

Obsessive-Compulsive Disorder

COMPLETED

Memantine for Refractory OCD Patients

NCT05015595

Obsessive-Compulsive Disorder

UNKNOWN PHASE3

Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder

NCT00211744

Obsessive-compulsive Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. Memantine is not FDA approved for OCD, but is approved for the treatment of Alzheimer's Disease. Memantine appears to work by regulating the activity of glutamate, one of the brain's specialized messenger chemicals, which may play a role in OCD. All patients in the study will receive memantine; no one will receive placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive-Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Memantine open label

All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.

Group Type EXPERIMENTAL

Memantine

Intervention Type DRUG

pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Memantine

pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Namenda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 18 years of age
* suffering from OCD
* Y-BOCS score of 18 or greater
* taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria

* diagnosed with a mental disorder other than OCD
* taking tiagabine or pregabalin
* having had a previous trial of memantine
* receiving therapy for OCD
* substance abuse in the last 6 months
* personality disorders sufficiently severe to interfere with study participation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No